Researchers NYU Grossman School of Medicine and University of California, Davis, analyzed cause-of-death data from the National Vital Statistics System from 3,109 counties nationwide between 2001 and 2017.
Healthcare providers in U.S. hospitals bear the brunt of the epidemic as they deal with the medical consequences of opioid addiction. From 1999 to 2017, Coverys says, more than 700,000 people died as a result of the opioid epidemic and the number of opioid-related overdoses grew sixfold.
ISMP respectfully concludes that little evidence was provided that should cause healthcare providers to abandon the use of judicious and well-placed independent double checks for selected high-alert medications. Instead, ISMP continues to believe that the selective and proper use of manual independent double checks plays an important role in medication safety.
In late 2018, KDMC sought to improve patient safety and streamline the medication reconciliation process by automating EHR transcription of critical medication data. The solution KDMC came up with has contributed to increased patient safety and better health outcomes, as well as higher nurse productivity.
U.S. overdose deaths—67.8% of which involve opioids—decreased last year for the first time in nearly three decades and are projected to decline another 3.4% this year. Other data show opioids are prescribed less often, and at lower dosages, than in the past.
The $205 billion attributable to excess healthcare spending between 2015 and 2018 included providing medical care for opioid addicts and infants born with neonatal opioid-related conditions, and other family members bearing costs associated with those diagnoses.
In this interview, Tim Vanderveen, PharmD, a consultant with ICU Medical, discusses IV therapy and its impact on patient safety.
Because new USP <800> Hazardous Drugs—Handling in Healthcare Settings refers to the other chapters, it is considered by USP to be “informational only” until the revisions are final. The Joint Commission has said it will continue to survey hospitals to the current USP compounding chapters but will expect hospitals to meet the requirements of local AHJs, as always.
USP <800> will still take effect on December 1. The Healthcare Quality and Safety team at USP explained that it would only be “informational and not compendially applicable.”
When given intraspinally instead of a local anesthetic, tranexamic acid is a potent neurotoxin with a mortality rate of about 50% and is almost always harmful to the patient. Survivors of intraspinal tranexamic acid injection often experience seizures, permanent neurological injury, and paraplegia.